Telligent Fund LP lowered its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 8.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,600 shares of the company’s stock after selling 600 shares during the period. Eli Lilly and Company comprises 7.9% of Telligent Fund LP’s holdings, making the stock its 4th largest position. Telligent Fund LP’s holdings in Eli Lilly and Company were worth $7,093,000 at the end of the most recent quarter.
Other large investors have also made changes to their positions in the company. Cidel Asset Management Inc. raised its holdings in shares of Eli Lilly and Company by 26.5% in the third quarter. Cidel Asset Management Inc. now owns 26,726 shares of the company’s stock valued at $20,392,000 after purchasing an additional 5,591 shares during the last quarter. Spire Wealth Management raised its holdings in shares of Eli Lilly and Company by 2.2% in the fourth quarter. Spire Wealth Management now owns 27,719 shares of the company’s stock valued at $29,789,000 after purchasing an additional 592 shares during the last quarter. Coldstream Capital Management Inc. raised its holdings in shares of Eli Lilly and Company by 25.6% in the third quarter. Coldstream Capital Management Inc. now owns 42,418 shares of the company’s stock valued at $32,365,000 after purchasing an additional 8,659 shares during the last quarter. Farther Finance Advisors LLC raised its holdings in shares of Eli Lilly and Company by 30.8% in the fourth quarter. Farther Finance Advisors LLC now owns 31,145 shares of the company’s stock valued at $33,471,000 after purchasing an additional 7,338 shares during the last quarter. Finally, Teachers Retirement System of The State of Kentucky raised its holdings in shares of Eli Lilly and Company by 3.5% in the third quarter. Teachers Retirement System of The State of Kentucky now owns 165,165 shares of the company’s stock valued at $126,022,000 after purchasing an additional 5,595 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.
Wall Street Analysts Forecast Growth
LLY has been the topic of a number of recent research reports. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $1,285.00 price objective on shares of Eli Lilly and Company in a report on Friday, March 6th. Leerink Partners set a $1,119.00 target price on Eli Lilly and Company in a research report on Tuesday. Wall Street Zen raised Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 2nd. CICC Research lifted their target price on Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the company a “neutral” rating in a research report on Wednesday, February 11th. Finally, HSBC downgraded Eli Lilly and Company from a “hold” rating to a “reduce” rating and lowered their target price for the company from $1,070.00 to $850.00 in a research report on Tuesday, March 17th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus target price of $1,227.00.
Key Eli Lilly and Company News
Here are the key news stories impacting Eli Lilly and Company this week:
- Positive Sentiment: CVS Caremark is restoring coverage for Zepbound and adding Foundayo to drug plans, and Lilly said all three of the largest U.S. pharmacy benefit managers now cover its full obesity portfolio, improving commercial access and revenue potential. Reuters: CVS brings back coverage for Lilly’s obesity drug Zepbound
- Positive Sentiment: Lilly announced three vaccine acquisitions worth up to about $3.8 billion, signaling a broader growth strategy beyond obesity and diabetes and potentially opening a new long-term market opportunity. Reuters coverage of Lilly vaccine acquisitions
- Positive Sentiment: New clinical data presented for Foundayo, Mounjaro, and retatrutide highlighted strong efficacy in obesity and diabetes, reinforcing investor confidence in Lilly’s cardiometabolic pipeline. PR Newswire: Lilly to present new data…
- Positive Sentiment: Several analysts reiterated bullish views and higher price targets, including a BofA target increase, which supports the stock’s momentum and valuation narrative. InsiderMonkey: Eli Lilly among safe stocks
- Neutral Sentiment: Lilly’s presentation at Bernstein and upcoming conference appearances are keeping investors focused on management commentary, but these events are more about confirming the existing growth story than creating a new catalyst. Seeking Alpha transcript
- Negative Sentiment: Some commentary argues Novo Nordisk may be a better short-term value, and Lilly’s rich valuation could limit upside if growth expectations slow. Motley Fool: Novo Nordisk Is A Better Buy Than Eli Lilly Right Now
Eli Lilly and Company Price Performance
Shares of LLY opened at $1,126.66 on Friday. The company has a market cap of $1.06 trillion, a price-to-earnings ratio of 40.02, a PEG ratio of 1.18 and a beta of 0.48. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,149.10. The company’s fifty day simple moving average is $952.15 and its 200 day simple moving average is $1,009.10. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. The firm had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The business’s revenue was up 55.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, research analysts forecast that Eli Lilly and Company will post 35.8 earnings per share for the current fiscal year.
Eli Lilly and Company Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Friday, May 15th. Eli Lilly and Company’s payout ratio is 24.58%.
Eli Lilly and Company Profile
Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.
Read More
- Five stocks we like better than Eli Lilly and Company
- China Deal Ignites Boeing’s Financial Afterburners
- 3 Stocks Rallying on Micron’s Price Boost: Substance or Hype?
- Snowflake and the Snowballing Impact of its AI Flywheel
- AI’s Biggest Bottleneck Could Make These 2 Stocks Soar
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
